RÉSUMÉ
Objective To explore the pharmacokinetic properties of curcumin nano emulsion and its pharmacodynamic effects on hyperlipidemia in rats. Methods The method for determination of curcumin was established by HPLC-MS. The pharmacokinetics characteristics of curcumin nano emulsion oral administration system were investigated. SD rats were used as model animals to establish hyperlipidemia animal models, and the pharmacodynamic effects of curcumin nano emulsion on hyperlipidemia induced by high fat diet was preliminarily investigated. Results The results of pharmacokinetic studies in vivo showed that the relative bioavailability of curcumin nano emulsion was 313.47% with bulk drug group as the reference preparation. The relative bioavailability of curcumin nano emulsion was 279.52 % with tablets as reference preparation. Cmax of curcumin nano emulsion group was 201.48 % of that of bulk drug group and 193.02 % of that of tablet group, and had higher MRT value (183.52 % of that of bulk drug group and 154.21 % of that of tablet group) than bulk drug group and tablet group. Pharmacodynamics research results showed that curcumin nano emulsion oral administration system could significantly reduce the levels of triglyceride and LDL-c in serum of model rats, and relieve liver lipid deposition and liver injury caused by high-fat diet in model animals. Conclusion The oral administration system of curcumin nano emulsion could effectively improve the bioavailability of curcumin, which has a good hypolipidemic effect. It also could control the weight gain of hyperlipidemia rats and improve the changes of liver coefficient caused by lipid metabolism disorder.
RÉSUMÉ
Based on national health insurance policy, traditional Chinese medicine (TCM) clinical practice and newly revealed pathological changes in Coronavirus Disease 2019 (COVID-19), the early TCM utilization was recommended to promote blood circulation and protect respiratory system. The fermented Ophiocordyceps powder preparations (Bailing tablets or capsules) are the top choice to inhibit the cytokine storm, relieve lung fibrosis and kidney damage.
RÉSUMÉ
Objective To develop a novel skin microdialysis technology in vivo,and to determine the pharmacokinetic of ba-icalin after transdermal administration in rats. Methods An HPLC-MS/MS method used for the determination of baicalin in skin mi-crodialysis samples was established ,SD rats were pretreated with skin microdialysis operation under anesthesia , and then the baicalin gel was applied to the skin surface of probe in vivo.The baicalin concentration of skin microdialysates was determined , the time curve of baicalin concentration was drawn and the topical pharmacokinetics parameters of percutaneous absorption was calculated. Results Baicalin was optimized at the transitions m/z 447.3→271.2.The linearity correlation was good and the assay exhibited good precision and accuracy.The subcutaneous probe recovery of baicalin in vivo was(24.40 ±0.91)%and was stable over the 240 min study peri-od.Baicalin could be detected in the microdialysis samples after transdermal administration , and its concentration continued to rise in 8 h.AUC0-t in skin tissue was(50.04 ±34.17) mg· min· L-1. Conclusion The method of skin microdialysis in vivo could be used in the local pharmacokinetic research of baicalin.